|
 |
|
|
|||
|
 |
|
Mar. 5, 2024 Source: Bayer news release Leverkusen/London - The Bayer Group achieved its adjusted guidance for 2023. In his speech at the Financial News Conference in London on Tuesday, CEO Bill Anderson took stock of the company's situation and looked toward the future. "We are a high-impact, mission-driven, life-science company with three strong businesses, but we have four challenges that urgently must be addressed," said Anderson, referring to the loss of exclusivities and the pipeline at Pharmaceuticals, the US litigation, the company's high debt levels and a hierarchical bureaucracy that blocks progress. For the next 24 to 36 months, the company will put its energy and focus into building a strong Pharmaceuticals pipeline, addressing litigation, reducing debt, and continuing to implement its radical new operating model Dynamic Shared Ownership (DSO) to improve performance, said Anderson. DSO will reduce hierarchy levels, cut bureaucracy, streamline structures and significantly accelerate decision-making. The company will be fully centered on customers and products, with each one of its businesses leaner and more effective than their competitors, explained Anderson. These steps will take out 2 billion euros in annual organizational costs from 2026, he noted, with cost reduction representing just one outcome. Ultimately, DSO will fuel growth through improved customer proximity and accelerated innovation, enabling a strengthening of the Pharma pipeline, for example. Further, DSO will enable Crop Science to strengthen its leading position in agriculture through generational innovation, with 10 blockbusters reaching the market over the next decade. Consumer Health will likewise be in a position to outperform its competition with its leading brands. In order to reduce legal risks and the related uncertainty, the company is updating its strategy and pursuing new approaches both inside and outside the courtroom. Bayer will also address its debt. The company aims to advance toward an A rating through profitable growth as well as a planned amendment to its dividend policy. Bayer has proposed to pay out the legally required minimum for three years, as previously announced. On the question of the company's structure and a possible break-up of the Group, "our answer is 'not now' - and this shouldn't be misunderstood as 'never'," said Anderson. "Of course, we will keep an open mind," he added. Given the company's very limited room to maneuver, "our priority is on tackling our challenges, boosting performance and creating strategic flexibility. We are convinced that this approach is what's best for Bayer." 2023: Sales and earnings decline, adjusted guidance met Looking at the company's performance in 2023, CFO Wolfgang Nickl said: "We achieved the revised outlook on all key financial metrics." Group sales came in at 47.637 billion euros, down 1.2 percent on a currency- and portfolio-adjusted basis (Fx & portfolio adj.). EBITDA before special items fell by 13.4 percent to 11.706 billion euros. This figure included a negative currency effect of 375 million euros (2022: positive currency effect of 429 million euros). "Due to lower target attainment, the expense for the Group-wide short-term incentive program declined across all divisions, falling by around 1 billion euros overall. In addition, the expense for the long-term incentive program was around 0.4 billion euros lower than in the previous year. The EBITDA margin before special items came in at 24.6 percent, down 2.0 percentage points against the prior year. EBIT amounted to 612 million euros (2022: 7.012 billion euros) after net special charges of 6.977 billion euros (2022: 2.245 billion euros). "The special charges mainly resulted from impairment losses, which were primarily attributable to the Crop Science Division. Net income came in at minus 2.941 billion euros (2022: plus 4.150 billion euros). Core earnings per share decreased by 19.5 percent to 6.39 euros." Free cash flow declined by 57.9 percent to 1.311 billion euros. Net financial debt as of December 31 increased by 8.5 percent against year-end 2022, to 34.498 billion euros. Cash inflows from operating activities and positive currency effects were unable to fully offset the outflow for the dividend payment and the settlement payments for the litigations in the United States. Crop Science records significant decline in sales and earnings against very strong prior year, mainly due to lower glyphosate prices Despite gains in Europe/Middle East/Africa and Asia/Pacific, Bayer's agricultural business (Crop Science) saw overall sales fall by 3.7 percent (Fx & portfolio adj.) to 23.270 billion euros. This decline was mainly attributable to significantly lower prices for glyphosate-based products due to reduced prices for generics, resulting in a 26.0 percent (Fx & portfolio adj.) decline in sales at Herbicides. Amid an inflation-driven market environment, the rest of the portfolio saw a positive price development overall, driven by innovative products and higher commodity prices. The Corn Seed & Traits business achieved the strongest growth, with sales rising 13.8 percent (Fx & portfolio adj.), primarily due to higher prices. Business was also up at Fungicides, which posted growth of 8.8 percent (Fx & portfolio adj.) that was mainly driven by higher prices in Europe/Middle East/Africa and increased volumes in Latin and North America. Sales at Soybean Seed & Traits advanced by 5.5 percent (Fx & portfolio adj.), mainly thanks to higher license revenues in Latin America. EBITDA before special items at Crop Science fell by 26.6 percent to 5.038 billion euros, primarily due to significant price declines for glyphosate-based products. Earnings were also diminished by a mainly inflation-related increase in the cost of goods sold. There was a positive currency effect of 103 million euros (2022: 284 million euros). The EBITDA margin before special items declined by 5.6 percentage points to 21.7 percent. To read the entire report click here. Tweet |
|
|
|
|
|
|
|
|
|||||||||||||
